Pharmaceutical composition
Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabetes.
1 . A pharmaceutical composition comprising an insulin sensitivity enhancer in combination with an insulin secretion enhancer, wherein the insulin sensitivity enhancer is 5-(4-(2-(5-ethyl-2-pyridyl)ethoxy)benzyl)-2,4-thiazolidinedione or its pharmacologically acceptable salt, and the insulin secretion enhancer is calcium (2S)-2-benzyl-3-(cis-hexahydro-2-isoindolinylcarbonyl)propionate dihydrate.
2 . The pharmaceutical composition of claim 1 , wherein the insulin sensitivity enhancer is pioglitazone or its hydrochloride.
3 . The pharmaceutical composition of claim 1 , comprising a mixture comprising a) the insulin sensitivity enhancer; b) the insulin secretion enhancer and c) a pharmaceutically acceptable carrier.
4 . The pharmaceutical composition of claim 1 , which is in an oral dosage form.
5 . The pharmaceutical composition of claim 1 , which a tablet, a capsule or a granule.
6 . A method of treating diabetes comprising administering to a mammal in need thereof a therapeutically effective amount of an insulin sensitivity enhancer in combination with an insulin secretion enhancer, wherein the insulin sensitivity enhancer is 5-(4-(2-(5-ethyl-2-pyridyl)ethoxy)benzyl)-2,4-thiazolidinedione or its pharmacologically acceptable salt, and the insulin secretion enhancer is calcium (2S)-2-benzyl-3-(cis-hexahydro-2-isoindolinylcarbonyl)propionate dihydrate.
7 . The method of claim 6 , wherein the insulin sensitivity enhancer is pioglitazone or its hydrochloride.
8 . The method of claim 6 , comprising administering a mixture comprising a) the insulin sensitivity enhancer; b) the insulin secretion enhancer and c) a pharmaceutically acceptable carrier.
9 . The method of claim 6 , comprising admixing a formulation comprising the insulin sensitivity enhancer and a formulation comprising the insulin secretion enhancer to form an admixture and administering said admixture to the mammal.
10 . The method of claim 6 , comprising administering to the mammal a first formulation comprising the insulin sensitivity enhancer and administering to the mammal a second formulation comprising the insulin secretion enhancer independently of each other.
11 . The method of claim 10 , wherein the first formulation and the second formulation are administered to the mammal concurrently.
12 . The method of claim 10 , wherein the formulation and the second formulation are administered to the mammal at staggered times.
13 . The method of claim 6 , wherein the mammal is a human subject.